Tirofiban Hydrochloride Monohydrate CAS NO.150915-40-5

Tirofiban hydrochloride monohydrate Basic information

Tirofiban hydrochloride monohydrate Physical and Chemical Properties

Tirofiban hydrochloride monohydrate Usage

Pharmacology

Platelet activation, adhesion and aggregation are the key initial steps for the formation of arterial thrombosis on the surface of atherosclerotic plaque rupture. Thrombosis is the acute coronary ischemic syndrome, namely unstable angina and myocardial infarction, and the heart after coronary angioplasty. The main pathophysiological problems of ischemic complications.

Tirofiban hydrochloride is a non-peptide reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, which is the main platelet surface receptor involved in the process of platelet aggregation. Tirofiban hydrochloride prevents fibrinogen from binding to glycoprotein IIb/IIIa, thereby blocking platelet cross-linking and platelet aggregation.

In vitro tests have shown that tirofiban hydrochloride can inhibit platelet aggregation induced by adenosine diphosphate (ADP) and prolong the bleeding time (BT) in healthy subjects and patients with coronary heart disease, which indicates that tirofiban hydrochloride can strongly inhibit Platelet function. The time of inhibition is parallel to the plasma concentration of the drug. After stopping tirofiban hydrochloride injection, platelet function quickly returned to the baseline level.

Tirofiban hydrochloride injection was infused for 4 hours at a rate of 0.15μg/kg/min. The combination with aspirin can inhibit platelet aggregation to the greatest extent, and has a mild additive effect on prolonging bleeding time.